Potato protease inhibitor II prevents obesity by inducing browning of white adipose tissue in mice via β3 adrenergic receptor signaling pathway

Phytother Res. 2022 Oct;36(10):3885-3899. doi: 10.1002/ptr.7451. Epub 2022 Aug 26.

Abstract

There are currently few effective and safe pharmacologic means for inducing beige adipogenesis in humans. This study highlights the role of potato protease inhibitor II (PPI II) in regulating the browning of adipose tissue. The in vitro results showed that PPI II increased the expression of the uncoupling protein 1 (UCP1) protein and gene and beige-specific genes, including Cd137, Cited1, Tbx1, and Tmem26 in vitro. PPI II treatment for three months in diet-induced obesity mice increased the levels of the UCP1 protein in white adipose tissue, causing elevated energy expenditure, thus preventing obesity and improving glucose tolerance. Mechanistic studies further revealed that PPI II regulated the abundance and activity of β3 adrenergic receptor (β3 -AR) in white adipocytes. Chemical-inhibition experiments revealed the crucial role of β3 -AR-dependent protein kinase A (PKA)-p38 kinase (p38)/extracellular signal-related kinase1/2 (ERK1/2) signaling in PPI II-mediated browning program of white adipose tissues. In summary, our findings highlight the role of PPI II in beige adipocyte differentiation and thermogenesis and provide new insights into its use in preventing obesity.

Keywords: browning; obesity; potato protease inhibitor II; white adipocyte tissue; β3-adrenergic receptor.

MeSH terms

  • Adipose Tissue, White
  • Animals
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Cyclic AMP-Dependent Protein Kinases / pharmacology
  • Glucose / metabolism
  • Humans
  • Mice
  • Mice, Obese
  • Obesity / drug therapy
  • Obesity / metabolism
  • Obesity / prevention & control
  • Protease Inhibitors / pharmacology
  • Signal Transduction
  • Solanum tuberosum* / metabolism
  • Thermogenesis
  • Uncoupling Protein 1 / genetics
  • Uncoupling Protein 1 / metabolism

Substances

  • Protease Inhibitors
  • Uncoupling Protein 1
  • Cyclic AMP-Dependent Protein Kinases
  • Glucose